AI Vinik, Q Zhang - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—HRQOL was evaluated in 217 subjects uncontrolled
with sulfonylurea plus metformin, enrolled in a 24-week, multicenter,
randomized, open-label, parallel-group trial of add-on insulin glargine ... Cited by 24 - Related articles - BL Direct - All 7 versions
JS Fischer, T McLaughlin, L Loza, R … - Current Medical Research and Opinion®, 2004 - informahealthcare.com 1Diabetes and Glandular Disease Clinic, San Antonio, TX, USA 2NDCHealth,
Phoenix, AZ, USA ... Address for correspondence: Dr Jerome S. Fischer, Diabetes
and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, ... Cited by 23 - Related articles - All 7 versions
[CITATION] Health-related quality of life and costs of receiving add-on therapy with insulin glargine or …
- Free from Publisher J Rosenstock, D Sugimoto, P Strange, JA … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—A1C improvements from baseline were similar in both groups (−1.7 vs.
−1.5% for insulin glargine vs. rosiglitazone, respectively); however, when
baseline A1C was >9.5%, the reduction of A1C with insulin glargine was ... Cited by 100 - Related articles - BL Direct - All 8 versions
S Boye, LS Matza, A Oglesby, K Malley, S … - Health and Quality of Life Outcomes, 2006 - biomedcentral.com Patient-reported measures can be used to examine whether drug differences other
than clinical efficacy have an impact on outcomes that may be important to
patients. Although exenatide and insulin glargine appear to have similar ... Cited by 18 - Related articles - Cached - All 11 versions
S Schwartz, R Sievers, P Strange, WH Lyness … - Diabetes care, 2003 - Am Diabetes Assoc RESULTS—At the end of study (week 24 of therapy), A1C and fasting plasma
glucose (FPG) values showed comparable decreases in the two treatment groups.
Only 31% (oral therapy) and 32% (insulin plus metformin) of subjects ... Cited by 9 - Related articles - BL Direct - All 6 versions
- Free from Publisher C Triplitt, L Glass, Y Miyazaki, E Wajcberg, A … - Diabetes care, 2006 - Am Diabetes Assoc RESULTS—A1C and FPG decreased similarly in the glargine insulin (9.1 ± 0.4 to
7.6 ± 0.3% and 212 ± 14 to 139 ± 5 mg/dl, respectively, both P < 0.0001) and
rosiglitazone (9.4 ± 0.3 to 7.6 ± 0.4% and 223 ± 14 to 160 ± 19 mg/dl, ... Cited by 9 - Related articles - BL Direct - All 6 versions
R Houlden, S Ross, S Harris, JF Yale, L … - Diabetes Research and Clinical Practice, 2007 - Elsevier The objective was to compare the impact on treatment satisfaction (TS) and
quality of life (QoL) of early insulinization with glargine versus adjusting
oral antidiabetic drug (OAD) therapy in people with Type 2 diabetes with ... Cited by 10 - Related articles - All 15 versions
TME Davis, RM Clifford, WA Davis - Diabetes research and clinical practice, 2001 - Elsevier Previous studies investigating the relationship between insulin therapy on
quality of life (QOL) in Type 2 diabetes have produced conflicting results that
may reflect differences in patient samples, study design and context. To ... Cited by 35 - Related articles - All 7 versions
HU Janka, G Plewe, K Busch - Journal of the American Geriatrics Society, 2007 - phx1.medscape.com Recent studies in patients with type 2 diabetes mellitus, although not performed
in older people, [10] demonstrate that insulin treatment is required to achieve
good glycemic control. [1] Consensus opinion on how or when to initiate ... Cited by 27 - Related articles - BL Direct - All 10 versions
